Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research8

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research8

FiltersClear all

Status

Recruiting2
Completed5
Terminated1

Study type

Interventional8

Phase

Phase 24
Not applicable3
Phase 31

Investigator

Karen Tang4
Jeremy Veenstra-VanderWeele1
Kevin Ching1
Stephen Kanne1
So Hyun Kim1

Department

Psychiatry7
Emergency Medicine1

Condition

Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34
Multiple Myeloma32

Intervention type

Drug5
Behavioral2
Other1

Sponsor type

Other academic3
Industry3
WCM (investigator-initiated)2

Start date

Has results posted1

Autism Spectrum Disorder×Clear all

Showing 1–8 of 8 studiesSort:

RecruitingInterventional · Phase 2NCT05999240 ↗
A Target Engagement Study of Pimavanserin for Behavioral Inflexibility With Open Label Trial for Rigid Rigid-compulsive Behavior in Adolescents and Adults With Autism
Karen TangPI
Intervention
Drug: Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID] · Drug: Placebo
Dates

FiltersClear all

Status

Recruiting2
Completed5
Terminated1

Study type

Interventional8

Phase

Phase 24
Not applicable3
Phase 31

Investigator

Karen Tang4
Jeremy Veenstra-VanderWeele1
Kevin Ching1
Stephen Kanne1
So Hyun Kim1

Department

Psychiatry7
Emergency Medicine1

Condition

Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34
Multiple Myeloma32

Intervention type

Drug5
Behavioral2
Other1

Sponsor type

Other academic3
Industry3
WCM (investigator-initiated)2

Start date

Has results posted1

Autism Spectrum Disorder×Clear all

Showing 1–8 of 8 studiesSort:

RecruitingInterventional · Phase 2NCT05999240 ↗
A Target Engagement Study of Pimavanserin for Behavioral Inflexibility With Open Label Trial for Rigid Rigid-compulsive Behavior in Adolescents and Adults With Autism
Karen TangPI
Intervention
Drug: Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID] · Drug: Placebo
Dates

Show all 50

Show fewer

Neoplasms32
Colitis, Ulcerative29
Atrial Fibrillation27
Carcinoma, Non-Small-Cell Lung27
Crohn Disease27
Recurrence27
COVID-1926
Myelodysplastic Syndromes26
Parkinson Disease24
Neoplasm Metastasis23
Obesity23
Colorectal Neoplasms19
HIV Infections19
Hematologic Neoplasms19
Cardiovascular Diseases18
Depression18
Non-alcoholic Fatty Liver Disease16
Overweight15
Lung Neoplasms14
Melanoma14
Cognitive Dysfunction13
Idiopathic Pulmonary Fibrosis13
Inflammatory Bowel Diseases13
Alzheimer Disease12
Leukemia12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Coronary Artery Disease11
Hypertension11
Hypertension, Pulmonary11
Lung Diseases, Interstitial11
Myeloproliferative Disorders11
Pulmonary Arterial Hypertension11
Stroke11
Chronic Pain10
Hemophilia A10
Leukemia, Myelomonocytic, Chronic10
Lymphoma, Follicular10
Lymphoma, Large B-Cell, Diffuse10
Urinary Bladder Neoplasms10
Burkitt Lymphoma9
Fibrosis9
Liver Diseases9
Carcinoma, Renal Cell8

Oct 2025 – Oct 2027 (est.)

Sponsor

Research Foundation for Mental Hygiene, Inc.

Autism Spectrum Disorder

RecruitingInterventional · Phase 2NCT07091279 ↗

Randomized Controlled Trial of Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism

Karen TangPI

Intervention: Drug: Propranolol · Drug: Placebo
Dates: Jan 2026 – Nov 2028 (est.)
Sponsor: New York State Pyschiatric Institute

Autism Spectrum DisorderChallenging BehaviourAggression+2 more

TerminatedInterventional · Phase 3NCT03504917 ↗

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension

Jeremy Veenstra-VanderWeelePI

Intervention: Drug: Balovaptan · Drug: Placebo
Dates: Aug 2018 – Mar 2020· Results posted
Sponsor: Research Foundation for Mental Hygiene, Inc.

Autism Spectrum Disorder

CompletedInterventional · Not applicableNCT04146428 ↗

Evaluating BOSCC and ELSA as Outcome Measures in the Context of a JASPER Intervention Trial

So Hyun KimPI

Intervention: Behavioral: clinician-mediated JASPER · Behavioral: parent-mediated JASPER
Dates: Apr 2021 – May 2025
Sponsor: Weill Medical College of Cornell University

Autism Spectrum Disorder

CompletedInterventional · Not applicableNCT04675580 ↗

Tele Toy Talk: Telehealth Language Intervention

Stephen KannePI

Intervention: Behavioral: Toy Talk
Dates: Dec 2020 – Jul 2022
Sponsor: Weill Medical College of Cornell University

Autism Spectrum Disorder

CompletedInterventional · Phase 2NCT05067582 ↗

A Randomized, Double-Blind, Chronic Dosing (12-weeks), Two-Period, Placebo-Controlled, Crossover, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Two Doses of L1-79 for the Treatment of the Core Deficits in Social-Communication Interaction in Adolescents and Young Adults With Autism Spectrum Disorder

Karen TangPI

Intervention: Drug: L1-79
Dates: Jan 2022 – Jun 2024
Sponsor: Yamo Pharmaceuticals

Autism Spectrum DisorderAutism

CompletedInterventional · Phase 2NCT05081245 ↗

A Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).

Karen TangPI

Intervention: Drug: ML-004 (IR)/(ER) tablet · Drug: ML-004 Placebo
Dates: Sep 2022 – Mar 2026
Sponsor: MapLight Therapeutics, Inc

Autism Spectrum Disorder

CompletedInterventional · Not applicableNCT05288868 ↗

The Effect of Simulation-based Training on Confidence and Competence in Obtaining Vitals in a Child With Autism

Kevin ChingPI

Intervention: Other: Educational Intervention: online didactic lecture and educational simulation activity
Dates: Jun 2022 – May 2024
Sponsor: Weill Medical College of Cornell University

Autism Spectrum Disorder